How Does Fulgent Company Work?

Fulgent Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How is Fulgent transforming post‑COVID genetic testing and diagnostics?

Fulgent shifted from COVID testing back to high-complexity genetic diagnostics, focusing on oncology, rare disease, reproductive health, biopharma services, and data assets. In 2024 it reported about $326 million revenue, 1.3–1.5M billable tests, and held over $900M in cash and marketable securities.

Fulgent combines next-generation sequencing, proprietary bioinformatics, and clinical interpretation to serve health systems, physicians, payors, and biopharma—balancing clinical volume with higher-margin pharma services and data monetization.

How does Fulgent’s platform, cost structure, and diversified revenue model work to create durable value and growth? See Fulgent Porter's Five Forces Analysis for strategic context.

Fulgent operates an integrated diagnostics platform combining in-house wet labs, proprietary bioinformatics, and CLIA/CAP-accredited facilities to deliver rapid, cost-efficient genomic and infectious disease testing across clinical and biopharma markets.

Integrated Laboratory Operations

Vertical integration: NGS, PCR, and ctDNA workflows run in-house with automated sample processing and validated LIMS to control quality and lower per-test costs.

Proprietary Bioinformatics

Internal pipelines handle variant calling, annotation, and clinical interpretation, enabling software-driven reports and rapid menu expansion across tests.

Comprehensive Test Menu

Offerings include hereditary/rare disease panels, oncology (solid tumor, hematologic, MRD/ctDNA, tissue/liquid biopsy), reproductive health (carrier, prenatal, NIPT), and regionally relevant infectious disease assays.

Biopharma Services

Assay development, companion diagnostic (CDx) work, clinical trial testing, and real-world evidence services support pharmaceutical and research partners.

Operations rely on automation, national logistics, and integrated digital workflows to shorten turnaround and support scale.

Operational Differentiators and Value

Key elements driving Fulgent's value proposition include cost discipline, rapid turnaround times, and embedded clinical integration that improve diagnostic utility and adoption.

• Turnaround: typical clinical assays return results in 2–7 days depending on complexity and sample type.
• Supply chain: uses major NGS vendors for sequencers/chemistry while retaining assay design and validation internally.
• Logistics and integration: national kit distribution, overnight carriers, and portals integrated with EHRs and digital reporting.
• Commercial model: direct sales, health-system contracting, and payer agreements supported by clinical consults and service teams.

Fulgent's software-enabled interpretation and payer-contracted pricing enable competitive list prices and institutional partnerships, embedding the company within oncology pathways and clinical workflows; see a market analysis in Competitors Landscape of Fulgent.

Fulgent SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Revenue Streams and Monetization Strategies for the company center on clinical diagnostics, pharma services, data licensing and residual infectious testing, with a shift after 2021 from COVID to higher-margin genetics and pharma work driving normalized gross margins and recurring enterprise contracts.

Clinical diagnostics — core revenue

Clinical testing was the largest revenue driver in 2024, accounting for an estimated 65–75% of revenue as COVID testing faded to low single digits.

Pharma and CDx services — fast growth

Pharma, custom assays and CDx partnerships contributed roughly 20–30% in 2024, with project-based pricing and higher gross margins versus routine clinical testing.

Data services and licensing

De-identified genomic datasets, variant databases and analytics tools comprised a single-digit share but represent strategic, high-margin, sticky revenue.

Residual infectious disease testing

Infectious disease testing fell to low single digits in 2024–2025, concentrated in institutional accounts and surveillance contracts.

Revenue mix and geography

Revenue remains >90% US-centric with selective international reference and partnership deals supporting growth outside the US.

Monetization levers

Bundled oncology panels, tiered reporting, cross-sell from hereditary to oncology, and enterprise health system agreements increase ARPU and contract stability.

Key pricing and contract features for how fulgent works include fee-for-service reimbursement from commercial payers, Medicare/Medicaid, institutions and self-pay, plus milestone and pass-through pricing for pharma projects, and growing licensing fees for genomic data and software platforms; see a practical growth analysis in Growth Strategy of Fulgent.

Revenue detail and levers

Concrete levers and metrics used to monetize services:

• Clinical diagnostics: move from COVID-dominated >70% (2021) to genetics-driven 65–75% (2024).
• Pharma/CDx: project-based contracts, higher gross margins, representing 20–30% in 2024.
• Data licensing: single-digit percent today; key to margin expansion and customer stickiness.
• Pricing strategies: contracted rates, bundled panels, tiered turnaround-time fees, add-on biomarker charges and enterprise volume discounts.

Fulgent PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Key milestones for the fulgent company include a rapid COVID scale-up (2020–2022) that built national testing capacity and funded a durable balance sheet, followed by oncology and biopharma expansion (2022–2025) focused on NGS, liquid biopsy, and CDx services to capture growing MRD and surveillance markets.

COVID scale-up (2020–2022)

Scaled testing to national capacity, producing multi-billion cumulative COVID revenues and accumulating a cash/securities position exceeding $900M by 2024 to support R&D and M&A.

Oncology expansion (2022–2025)

Launched tissue NGS, liquid biopsy/ctDNA assays and advanced MRD offerings targeting a surveillance and therapy monitoring market forecast at $3–5B globally by late decade.

Biopharma and CDx ramp

Expanded trial testing and companion diagnostic partnerships to align with oncology pipelines, increasing non-reimbursement revenue from pharma services and clinical trials.

Technology and automation

Invested in LIMS, bioinformatics, AI-driven variant interpretation and robotics to lower cost per test and turnaround time while strengthening EHR integrations and digital ordering portals.

The fulgent services strategy balanced rapid growth with discipline, shifting resources from COVID testing to oncology and pharma services while addressing reimbursement variability and competitive pressure from national and specialty labs.

Competitive edge and challenges

Competitive advantages include end-to-end platform control, speed-to-launch for new assays, pricing flexibility from low unit costs, and a strong cash position to fund R&D and M&A; notable challenges were revenue normalization post-COVID and reimbursement scrutiny in genetic testing.

• Maintained a cash/securities buffer above $900M by 2024 to support strategic pivots and investments
• Leveraged automation and AI to improve fulgent genetic sequencing workflow for clinicians and reduce fulgent lab turnaround time for results
• Grew fulgent labs business model into biopharma services and CDx to diversify fulgent revenue sources and partnerships
• Expanded payer and health system agreements to stabilize collections and covered lives

For context on company origins and evolution see Brief History of Fulgent

Fulgent Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Fulgent competes in a global genetic testing market projected to exceed $25–30B by 2030, with oncology NGS and MRD growing fastest (ctDNA/MRD >20% CAGR). The company holds a modest but rising oncology share while maintaining meaningful hereditary and reproductive testing volumes, supported by integrated workflows, payer contracts, and biopharma partnerships.

Industry Position

Fulgent company leverages scalable sequencing and automation to serve clinical and pharma markets. It competes on cost, turnaround time, and integrated diagnostics platform capabilities against larger hospital-backed labs and specialized oncology leaders.

Market Footprint

Revenue mix includes hereditary, reproductive, oncology, and COVID-era services; management targets oncology (tissue, ctDNA, MRD) and pharma/CDx to drive higher-margin growth. Customer stickiness arises from payer agreements and biopharma collaborations.

Key Risks

Principal risks include reimbursement shifts, rapid sequencing technology changes, regulatory evolution, pricing pressure, and post-COVID volume comparisons that can compress margins and growth.

Execution Challenges

Scaling MRD sensitivity/specificity, winning CDx contracts, and meeting RWE standards for MRD are material execution risks; competitive entrants and ultra-low-cost sequencing could erode pricing power.

Management outlook emphasizes oncology expansion, pharma services, and data monetization, supported by substantial cash to fund assay innovation, automation, and targeted M&A to avoid dilution and restore margins.

Outlook & Targets

If payer coverage improves and biopharma ties deepen, Fulgent can lift normalized gross margins toward pre-COVID high 30s–40s% and target double-digit clinical and pharma CAGR through 2026–2027.

• Market context: global genetic testing > $25–30B by 2030 with ctDNA/MRD >20% CAGR
• Financial posture: substantial cash to fund R&D, automation, and selective acquisitions
• Competitive pressure: hospital network labs and specialized oncology players retain advantages
• Regulatory risk: EU IVDR and finalized US FDA LDT oversight in 2024–2025 increase compliance burden

For additional context on target customer segments and addressable markets see Target Market of Fulgent.

Fulgent Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔